Melanie B. Thomas, MD, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).
Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibodyPF-03446962 in hepatocellular carcinoma (HCC).
<<<
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More